Company Avacta Group Plc London S.E.

Equities

GB0033519546

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote London S.E. Other stock markets
- ^GBX	-

Apr. 22	First Tin updates Tellerhauser estimates	AN
Apr. 10	Transcript : Avacta Group Plc - Special Call

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

GBP in Million	2021	Weight	2022	Weight	Delta
Therapeutics 56.8 %	2	73.5 %	5	56.8 %	+153.52%
Diagnostics 43.2 %	1	26.5 %	4	43.2 %	+435.56%

GBP in Million	2021	Weight	2022	Weight	Delta
South Korea 56.8 %	1	47.6 %	5	56.8 %	+291.50%
United Kingdom 26.2 %	1	18.4 %	3	26.2 %	+368.89%
France 13.4 %	-	-	1	13.4 %	-
North America 1.9 %	1	27.7 %	0	1.9 %	-78.04%
Rest of Europe 1.6 %	0	3.8 %	0	1.6 %	+42.34%
Rest of Asia 0.1 %	0	2.5 %	0	0.1 %	-90.54%

Managers	Title	Age	Since
Alastair Smith FOU	Founder	-	03-12-31
Tony Gardiner DFI	Director of Finance/CFO	53	16-01-03
Matt Johnson CTO	Chief Tech/Sci/R&D Officer	-	13-09-15
Michael Vinegrad IRO	Public Communications Contact	-	14-05-31
Neil Bell PRN	Corporate Officer/Principal	-	20-06-30
Simon Bennett PRN	Corporate Officer/Principal	-	Dec. 18

Members of the board	Title	Age	Since
Trevor Nicholls BRD	Director/Board Member	67	13-08-01
Alastair Smith FOU	Founder	-	03-12-31
Tony Gardiner DFI	Director of Finance/CFO	53	16-01-03
Paul Fry BRD	Director/Board Member	58	20-02-02
Eliot Forster CHM	Chairman	58	18-06-10
Mark Goldberg BRD	Director/Board Member	69	21-08-17
Shaun Chilton BRD	Director/Board Member	57	23-06-18
Christina Coughlin BRD	Director/Board Member	54	22-03-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	359,042,104	253,687,359 ( 70.66 %)	0	70.66 %

Name	Equities	%	Valuation
Hargreaves Lansdown Asset Management Ltd. 6.596 %	23,119,000	6.596 %	15 M p
Jarvis Investment Management Ltd. 6.126 %	21,472,000	6.126 %	13 M p
Conifer Management LLC 3.382 %	11,854,734	3.382 %	7 M p
Baillie Gifford & Co. 2.888 %	10,124,371	2.888 %	6 M p
IG Markets Ltd. 2.271 %	7,961,000	2.271 %	5 M p
HSBC Global Asset Management (UK) Ltd. 1.724 %	6,043,000	1.724 %	4 M p
Unicorn Asset Management Ltd. 1.227 %	4,300,000	1.227 %	3 M p
Premier Fund Managers Ltd. 1.042 %	3,652,532	1.042 %	2 M p
Avacta Group PLC JSOP 0.7934 %	2,781,000	0.7934 %	2 M p
HSBC Bank Plc (Market-Maker) 0.7478 %	2,621,000	0.7478 %	2 M p

Avacta Group Plc

Thorp Arch Estate Ash Way, Wetherby

LS23 7FA, Leeds

+44 1904 217 070

http://www.avacta.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs